Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Remond J A Fijneman"'
Autor:
Iris van ’t Erve, Bahar Alipanahi, Keith Lumbard, Zachary L. Skidmore, Lorenzo Rinaldi, Laurel K. Millberg, Jacob Carey, Bryan Chesnick, Stephen Cristiano, Carter Portwood, Tony Wu, Erica Peters, Karen Bolhuis, Cornelis J. A. Punt, Jennifer Tom, Peter B. Bach, Nicholas C. Dracopoli, Gerrit A. Meijer, Robert B. Scharpf, Victor E. Velculescu, Remond J. A. Fijneman, Alessandro Leal
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction,
Externí odkaz:
https://doaj.org/article/8005c4ee68144cd383ff212f1b67d00a
Autor:
Meike de Wit, Beatriz Carvalho, Pien M Delis-van Diemen, Carolien van Alphen, Jeroen A M Beliën, Gerrit A Meijer, Remond J A Fijneman
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0174768 (2017)
One prominent event associated with colorectal adenoma-to-carcinoma progression is genomic instability. Approximately 85% of colorectal cancer cases exhibit chromosomal instability characterized by accumulation of chromosome copy number aberrations (
Externí odkaz:
https://doaj.org/article/4d22f82cf01c4564be86644d60d7f6fe
High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.
Autor:
Evert van den Broek, Maurits J J Dijkstra, Oscar Krijgsman, Daoud Sie, Josien C Haan, Joleen J H Traets, Mark A van de Wiel, Iris D Nagtegaal, Cornelis J A Punt, Beatriz Carvalho, Bauke Ylstra, Sanne Abeln, Gerrit A Meijer, Remond J A Fijneman
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138141 (2015)
Cancer is caused by somatic DNA alterations such as gene point mutations, DNA copy number aberrations (CNA) and structural variants (SVs). Genome-wide analyses of SVs in large sample series with well-documented clinical information are still scarce.
Externí odkaz:
https://doaj.org/article/fabc696979d24c22ae1c2ca895da5a61
Autor:
Astrid Kramer, Marjolein J. E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, Daan van den Broek, Miriam Koopman, Jeanine M. L. Roodhart, Remond J. A. Fijneman, Valesca P. Retèl, Veerle M. H. Coupé
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative circulating
Externí odkaz:
https://doaj.org/article/df477bb60b4f45289ac535ad731952c5
Autor:
Lei Quan, Alphons P M Stassen, Claudia A L Ruivenkamp, Tom van Wezel, Remond J A Fijneman, Alan Hutson, Neelima Kakarlapudi, Augustinus A M Hart, Peter Demant
Publikováno v:
PLoS ONE, Vol 6, Iss 2, p e14727 (2011)
Genetic predisposition controlled by susceptibility quantitative trait loci (QTLs) contributes to a large proportion of common cancers. Studies of genetics of cancer susceptibility, however, did not address systematically the relationship between sus
Externí odkaz:
https://doaj.org/article/b6893b5a58eb4289b8c8355a067f5dda
Autor:
Aleksandra Stanojevic, Jelena Spasic, Mladen Marinkovic, Suzana Stojanovic-Rundic, Radmila Jankovic, Ana Djuric, Jerome Zoidakis, Remond J. A. Fijneman, Sergi Castellvi-Bel, Milena Cavic
Publikováno v:
Frontiers in Genetics, Vol 14 (2024)
Background: Methylenetetrahydrofolate reductase (MTHFR) single nucleotide polymorphisms (SNPs) have been suggested as risk, prognostic, and predictive factors for colorectal cancer in various populations, but have not been validated so far. The aim o
Externí odkaz:
https://doaj.org/article/28344242e5054711ab1e8ccbb4f46225
Autor:
Mladen Marinkovic, Suzana Stojanovic-Rundic, Aleksandra Stanojevic, Marija Ostojic, Dusica Gavrilovic, Radmila Jankovic, Natasa Maksimovic, Rafael Stroggilos, Jerome Zoidakis, Sergi Castellví-Bel, Remond J. A. Fijneman, Milena Cavic
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Introduction: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from nCRT, there is a need for predictive biomarkers. The aim of this study was to e
Externí odkaz:
https://doaj.org/article/6fba8ca2e4e6468bb9faa382c9c3f5d9
Autor:
Aleksandra Stanojevic, Martina Samiotaki, Vasiliki Lygirou, Mladen Marinkovic, Vladimir Nikolic, Suzana Stojanovic-Rundic, Radmila Jankovic, Antonia Vlahou, George Panayotou, Remond J. A. Fijneman, Sergi Castellví-Bel, Jerome Zoidakis, Milena Cavic
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 20, p 15412 (2023)
Locally advanced rectal cancer (LARC) presents a challenge in identifying molecular markers linked to the response to neoadjuvant chemoradiotherapy (nCRT). This study aimed to utilize a sensitive proteomic method, data-independent mass spectrometry (
Externí odkaz:
https://doaj.org/article/6f04933362a64d168e611d47a013ad9f
Autor:
G E Wensink, Karen Bolhuis, Marloes A G Elferink, Remond J A Fijneman, Onno Kranenburg, Inne H M Borel Rinkes, Miriam Koopman, Rutger-Jan Swijnenburg, Geraldine R Vink, Jeroen Hagendoorn, Cornelis J A Punt, Jeanine M L Roodhart, Sjoerd G Elias
Publikováno v:
The British journal of surgery, 110(3), 362-371. John Wiley and Sons Ltd
BackgroundPatients who develop early extrahepatic recurrence (EHR) may not benefit from local treatment of colorectal liver metastases (CRLMs). This study aimed to develop a prediction model for early EHR after local treatment of CRLMs using a nation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9f4de938dbebf88c099d8b3676ae39d
https://doi.org/10.1093/bjs/znac461
https://doi.org/10.1093/bjs/znac461
Autor:
Suzanna J. Schraa, Ellen Stelloo, Miangela M. Laclé, Joost F. Swennenhuis, Lodewijk A. A. Brosens, Remond J. A. Fijneman, Harma Feitsma, Miriam Koopman, Wendy W. de Leng, Geraldine R. Vink, Guus M. Bol
Publikováno v:
Virchows Archiv.
Tropomyosin receptor kinase (TRK) inhibitors have been approved for metastatic solid tumors harboring NTRK fusions, but the detection of NTRK fusions is challenging. International guidelines recommend pan-TRK immunohistochemistry (IHC) screening foll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb6563cf0411ff046658a377afb49e35
https://doi.org/10.1007/s00428-023-03538-1
https://doi.org/10.1007/s00428-023-03538-1